Abstract
Serum thyrotrophin receptor antibody (TRAb) and thyroid stimulating hormone (TSH) (IRMA) levels were measured in 38 patients at one month after the end of a course of carbimazole/T3 therapy for Graves' disease. Despite the increased sensitivity of the IRMA assay a TSH measurement at this stage was found to be of no predictive value, in contrast to estimation of serum TRAb levels which correctly predicted relapse and remission in 90% of patients.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dahlberg P. A., Karlsson F. A., Jansson R., Wide L. Thyrotropin-releasing hormone testing during antithyroid drug treatment of Graves' disease as an indicator of remission. J Clin Endocrinol Metab. 1985 Dec;61(6):1100–1104. doi: 10.1210/jcem-61-6-1100. [DOI] [PubMed] [Google Scholar]
- McGregor A. M., Smith B. R., Hall R., Petersen M. M., Miller M., Dewar P. J. Prediction of relapse in hyperthyroid Graves' disease. Lancet. 1980 May 24;1(8178):1101–1103. doi: 10.1016/s0140-6736(80)91551-2. [DOI] [PubMed] [Google Scholar]
- Wilson R., McKillop J. H., Pearson D. W., Cuthbert G. F., Thomson J. A. Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels. J Nucl Med. 1985 Sep;26(9):1024–1028. [PubMed] [Google Scholar]